[November 27, 2015] |
|
Research and Markets: Choroidal Neovascularization - Pipeline Analysis & Review, H2 2015
Research and Markets (http://www.researchandmarkets.com/research/kxvtp3/choroidal)
has announced the addition of the "Choroidal
Neovascularization - Pipeline Review, H2 2015" report to their
offering.
The report, Choroidal Neovascularization - Pipeline Review, H2 2015,
provides an overview of the Choroidal Neovascularization's therapeutic
pipeline. This report provides comprehensive information on the
therapeutic development for Choroidal Neovascularization, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases.
It also reviews key players involved in the therapeutic development for
Choroidal Neovascularization and special features on late-stage and
discontinued projects.
Key Topics Covered:
-
Snapshot of the global therapeutic landscape of Choroidal
Neovascularization
-
Key pipeline products under drug profile section which includes
product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
-
Key players involved in the therapeutics development for Choroidal
Neovascularizaion and enlists all their major and minor projects
-
All dormant and discontinued pipeline projects
-
Choroidal Neovascularization products under development by companies
and universities/research institutes based on information derived from
company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
Detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Choroidal Neovascularization pipeline on the basis of
target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Benefits of this Report:
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Choroidal Neovascularization
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Choroidal Neovascularization pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Affitech A/S
-
Aprogen, Inc.
-
F. Hoffmann-La Roche Ltd.
-
Genentech, Inc.
-
Iconic Therapeutics, Inc.
-
Mabion SA
-
Navigen Pharmaceuticals, Inc.
-
Noxxon Pharma AG
-
Promedior, Inc.
-
Regeneron Pharmaceuticals, Inc.
-
Sanwa Kagaku Kenkyusho Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/kxvtp3/choroidal
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005409/en/
[ Back To TMCnet.com's Homepage ]
|